SCHEMBL4133162

SCHEMBL4133162

CC(=O)c1cccc(Nc2cc(Cl)nc(N3CCC(O)CC3)c2)c1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.42
HPGD P15428 1/20 0.42
POLB P06746 1/20 0.41
ALOX5 P09917 1/20 0.41
ALDH1A1 P00352 1/20 0.40
MAPT P10636 3/20 0.40
RAD52 P43351 1/20 0.40
ATM Q13315 1/20 0.40
TP53 P04637 1/20 0.39
SCN9A Q15858 2/20 0.39
IDH2 P48735 1/20 0.39
NPC1 O15118 2/20 0.39
TDP1 Q9NUW8 1/20 0.39
PKM P14618 1/20 0.39
ALOX15 P16050 1/20 0.39
RAB9A P51151 1/20 0.39
EGFR P00533 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4361525 0.88 HTT (0.46) MAPTNPC1RAB9A
SCHEMBL4363470 0.85 NPC1 (0.52) POLBALOX5ALDH1A1MAPTTP53
SCHEMBL13621843 0.80 ALOX5 (0.53) GAAHPGDPOLBALOX5ALDH1A1
SCHEMBL3451728 0.78 MEN1 (0.48) POLBALDH1A1MAPTSCN9AIDH2
SCHEMBL13632605 0.77 GAA (0.39) GAAMAPTIDH2ALOX15EGFR
SCHEMBL13632528 0.76 NPC1 (0.50) GAAHPGDMAPTNPC1TDP1
SCHEMBL9984927 0.75 MAPT (0.42) GAAPOLBALDH1A1MAPTNPC1
SCHEMBL4129967 0.74 HTT (0.43) GAAHPGDPOLBALDH1A1MAPT
SCHEMBL3998633 0.73 PTGS2 (0.59) GAAPOLBALDH1A1MAPTATM
SCHEMBL4138095 0.71 GALR2 (0.45)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1805142-A4 NOVEL PYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM REDDY US THERAPEUTICS INC (US) 2009-06-10 EP claimed
EP-1805142-A2 NOVEL PYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM Reddy US Therapeutics, Inc. (US) 2007-07-11 EP claimed
US-20060084644-A1 Novel pyridine compounds, process for their preparation and compositions containing them DR. REDDY'S LABORATORIES LTD. (IN) 2006-04-20 US claimed
WO-2006034474-A2 NOVEL PYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM REDDY US THERAPEUTICS, INC. (US) 2006-03-30 WO claimed
US-7622486-B2 Pyridine compounds, process for their preparation and compositions containing them REDDY US THERAPEUTICS, INC. (US) 2009-11-24 US disclosed
US-7622486-B2 Pyridine compounds, process for their preparation and compositions containing them REDDY US THERAPEUTICS, INC. (US) 2009-11-24 US disclosed
US-7622486-B2 Pyridine compounds, process for their preparation and compositions containing them REDDY US THERAPEUTICS, INC. (US) 2009-11-24 US disclosed
US-20060084644-A1 Novel pyridine compounds, process for their preparation and compositions containing them DR. REDDY'S LABORATORIES LTD. (IN) 2006-04-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060084644-A1 Novel pyridine compounds, process for their preparation and compositions containing them LDLR, LRP6, PLPBP GAA 2018/4885HPGD 669/4885POLB 4210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.